Scientific instrument company Bruker (NASDAQ:BRKR). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 11% year on year to $801.4 million. The company’s full-year revenue guidance of $3.52 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $0.47 per share was 5.9% above analysts’ consensus estimates.
Is now the time to buy BRKR? Find out in our full research report (it’s free).
Bruker (BRKR) Q1 CY2025 Highlights:
- Revenue: $801.4 million vs analyst estimates of $768.5 million (11% year-on-year growth, 4.3% beat)
- Adjusted EPS: $0.47 vs analyst estimates of $0.44 (5.9% beat)
- The company slightly lifted its revenue guidance for the full year to $3.52 billion at the midpoint from $3.51 billion
- Management lowered its full-year Adjusted EPS guidance to $2.44 at the midpoint, a 9.5% decrease
- Operating Margin: 4%, down from 9% in the same quarter last year
- Organic Revenue rose 2.9% year on year (1.6% in the same quarter last year)
- Market Capitalization: $6.16 billion
StockStory’s Take
Bruker’s first quarter results reflected both the company’s diversified customer base and the impact of recent acquisitions. CEO Frank Laukien highlighted that biopharma demand strengthened, and the Bruker Scientific Instruments segment achieved 5.1% organic growth, despite declining U.S. and China academic/government orders. Laukien noted that “our teams executed very well under significant uncertainties in key markets,” and credited new product launches in spatial biology and molecular diagnostics for supporting growth. The company’s BioSpin and CALID groups benefited from robust research and diagnostics activity, but the BEST segment saw a decline due to weaker MRI superconductor demand and tough comparisons from last year. Management remained cautious about the sustainability of academic/government funding, emphasizing that delayed China stimulus and new tariffs weighed on segment performance.
Looking ahead, Bruker’s updated guidance reflects both ongoing challenges and mitigation strategies. CEO Frank Laukien explained that U.S. policy changes and tariffs are expected to create a $100 million gross revenue headwind this year, mostly from academic/government market pressures. At the same time, Laukien outlined actions to offset these impacts, including pricing adjustments, supply chain reengineering, and cost management. CFO Gerald Herman added that mitigation efforts should cover more than half of the operating profit headwind in 2025, with full offset expected by 2026. Management remains focused on product innovation and international growth, while acknowledging that further clarity on U.S. federal research policy and global tariffs will be critical for medium-term outlooks.
Key Insights from Management’s Remarks
Management attributed first quarter growth to biopharma demand, recent acquisitions, and new product launches, but acknowledged that academic/government funding reductions and tariffs are creating significant headwinds for certain segments.
- Biopharma momentum: Bruker saw continued improvement in biopharma demand, with CEO Frank Laukien stating that "biopharma has been increasing from a weak base last year" and is now supported by a broader set of tools, including spatial biology and automation platforms. This trend helped offset challenges in the academic/government sector.
- Academic/government weakness: The company experienced a notable decline in U.S. academic and government (ACA/GOV) orders, with Laukien estimating a 20-25% revenue drop for this market in 2025. Management reported delays but not cancellations so far, and expressed uncertainty about when NIH and NSF funding would stabilize.
- Impact of tariffs and policy: Bruker quantified a $100 million gross revenue headwind from U.S. federal funding changes, lower China stimulus, and new import tariffs—especially a 125% Chinese tariff on some U.S. exports. CFO Gerald Herman explained that about $90 million of operating profit is at risk before mitigation actions.
- Recent acquisitions and product launches: The company launched new products in spatial biology, NMR (nuclear magnetic resonance), and molecular diagnostics, while integrating acquisitions like Chemspeed and ELITech. Laukien described these as "meaningful post-genomic innovations" that support growth outside of volatile funding sources.
- Cost and supply chain actions: To address margin pressures, Bruker is implementing targeted price increases, cost reductions, and supply network changes. Laukien said these efforts should offset more than half of the 2025 headwinds, with the remainder addressed by 2026 through further operational changes.
Drivers of Future Performance
Bruker’s outlook for 2025 is shaped by anticipated weakness in academic and government markets, tariff impacts, and the pace of mitigation measures, with product innovation and international expansion as key offsetting factors.
- Mitigation of margin headwinds: Management expects pricing actions, cost controls, and supply chain reengineering to offset over half of the 2025 operating profit headwind, with benefits accelerating in the second half of the year and fully realized in 2026. Gerald Herman noted that supply chain adjustments and workforce flexibility, especially in Europe, will help manage fixed costs.
- Product innovation and diversification: Bruker is relying on new launches in spatial biology, molecular diagnostics, and automation to drive demand in biopharma and industrial markets. Laukien emphasized that recent acquisitions and expanded product offerings are helping to reduce reliance on academic/government funding and diversify revenue streams.
- Academic/government funding and tariffs remain risks: Management cautioned that further declines in U.S. and China academic/government funding, as well as uncertainty around future tariff policies, could continue to pressure results. The company has not assumed any major improvement in China stimulus or U.S. federal research budgets for the remainder of 2025.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will focus on (1) evidence that cost and supply chain mitigation actions are offsetting margin and revenue headwinds as planned, (2) stabilization or recovery in U.S. and China academic/government funding trends, and (3) continued growth in biopharma and diagnostics segments supported by new product launches. Progress on integrating recent acquisitions and clarity on global tariff policies will also be key indicators.
Bruker currently trades at a forward P/E ratio of 14.7×. Should you double down or take your chips? Find out in our full research report (it’s free).
High Quality Stocks for All Market Conditions
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.